Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.45 |
| ▸ | CTSD | P07339 | 6/20 | 0.45 |
| ▸ | CTSE | P14091 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086316 | 0.92 | BACE1 (0.54) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL2084208 | 0.92 | BACE1 (0.45) | BACE1CTSDCTSEKCNH2BACE2 | |
| SCHEMBL2087055 | 0.91 | BACE1 (0.49) | BACE1CTSDKCNH2BACE2PDK2 | |
| SCHEMBL2085929 | 0.91 | BACE1 (0.42) | BACE1CTSDKCNH2BACE2PDK2 | |
| SCHEMBL2085002 | 0.90 | BACE1 (0.51) | BACE1CTSDKCNH2BACE2REN | |
| SCHEMBL2085758 | 0.88 | BACE1 (0.54) | BACE1CTSDBACE2REN | |
| SCHEMBL2084579 | 0.88 | BACE1 (0.45) | BACE1CTSDKCNH2BACE2CYP11B1 | |
| SCHEMBL2085924 | 0.87 | BACE1 (0.47) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL2083839 | 0.84 | BACE1 (0.59) | BACE1CTSDKCNH2BACE2PDK2 | |
| SCHEMBL2085935 | 0.83 | BACE1 (0.41) | BACE1CTSDKCNH2BACE2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | claimed |
| EP-2035378-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | claimed |
| US-20110059992-A1 | New Compounds | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-7855213-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-12-21 | — | — | US | disclosed |
| EP-2035378-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080171771-A1 | New Compounds 391 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2007149033-A1 | SUBSTITUTED ISOINDOLES AS BACE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059992-A1 | New Compounds | MAPT, PSEN2, PSEN1 | BACE1 5/4885CTSD 1916/4885CTSE 1603/4885 |
| US-20080171771-A1 | New Compounds 391 | PSEN2, PSEN1, MAPT | BACE1 4/4885CTSD 1715/4885CTSE 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.